AUSTRALIAN COMMISSION
ON SAFETY AND QUALITY IN HEALTH CARE

Active ingredient prescribing

List of Medicines for Brand Consideration

December 2020

Published by the Australian Commission on Safety and Quality in Health Care.

Level 5, 255 Elizabeth Street, Sydney NSW 2000
Phone: (02) 9126 3600
Email: **mail@safetyandquality.gov.au**
Website: **www.safetyandquality.gov.au**

ISBN: 978-1-922563-00-2

The Commission's preference is that you attribute this publication (and any material sourced from it) using the following citation:

Australian Commission on Safety and Quality in Health Care. Active ingredient prescribing – List of Medicines for Brand Consideration. Sydney: ACSQHC; 2020.

Disclaimer

The content of this document is published in good faith by the Australian Commission on Safety and Quality in Health Care for information purposes. The document is not intended to provide guidance on particular healthcare choices. You should contact your health care provider on particular healthcare choices.
The Commission does not accept any legal liability for any injury, loss or damage incurred by the use of, or reliance on, this document.

Contents

Introduction

In October 2019 the *National Health (Pharmaceutical Benefits) Amendment (Active Ingredient Prescribing) Regulations 2019*, and the *Veterans' Affairs Pharmaceutical Benefits Schemes (Electronic Prescriptions and Active Ingredient Prescribing) Amendment Instrument 2019* mandated active ingredient prescribing.

Active ingredient prescribing uses standardised International Non-proprietary Names (INN) for medicines and will apply for most Pharmaceutical Benefits Scheme (PBS)/Repatriation Pharmaceutical Benefits Scheme (RPBS) items. From 1 February 2021 most prescriptions generated for supply under the PBS and the RPBS must meet the revised arrangements to be eligible for subsidy.

The Australian Commission on Safety and Quality in Health Care (the Commission) has been engaged by the Australian Government Department of Health to generate and maintain the following active ingredient prescribing clinical support documents:

- ***Active ingredient prescribing – User guide for Australian prescribers*** (user guide)*
- **List of Medicines for Brand Consideration** (LMBC)†
- **List of Excluded Medicinal Items** (LEMI)‡.

The user guide supports prescribers to prescribe medicines by the active ingredient with best practice guidance for specification of brand. Principles are outlined in the user guide to determine when prescribers should consider brand name specification if clinically necessary. Specifying the brand name may be necessary to support safe and quality use of a medicine where consumer harm could result from switching between medicine brands or to ensure prescriber instructions are suitable for the dispensed medicine.

This **List of Medicines for Brand Consideration** includes medicines prescribers should consider prescribing by brand as well as active ingredient, if clinically necessary for the treatment of their patient. For example, in situations where formulations are not interchangeable due to variations in delivery of the active ingredient, prescribers should consider specification by brand for patient safety.

Clinical software systems will alert prescribers when a prescribed medicine is on the List of Medicines for Brand Consideration. The alert will advise the prescriber to consider what should be included on the prescription for patient safety. The alert will include a hyperlink to the List of Medicines for Brand Consideration giving prescribers easy access to the list. Prescribers will action an additional step either to read the list or ignore before prescribing a medicine on the List of Medicines for Brand Consideration.

The List of Medicines for Brand Consideration is to be reviewed at least twice a year by the Commission, according to the principles in the user guide and in consultation with the Australian Government Department of Health and the Therapeutic Goods Administration.

A list of medicines and non-medicinal items which are exempt from active ingredient prescribing requirements has also been developed to support prescribers (List of Excluded Medicinal Items). These items should be prescribed by brand only for practical and safety purposes.

The *Active ingredient prescribing – User guide for Australian prescribers* provides full details on the implementation of active ingredient prescribing and the associated List of Medicines for Brand Consideration and the List of Excluded Medicinal Items.

---

* Therapeutic Goods Act 1989. Latest 22 January 2019. Available from **www.legislation.gov.au/Series/C2004A03952** [Accessed 23 September 2019].

† Health Literacy – Medication literacy definition. FIP Foundation for Education and Research (2017). Available from **www.fipfoundation.org/health-literacy/medication-literacy-definition/** [Accessed 4 December 2019].

‡ Medicines reimbursement policies in Europe. WHO Regional Office for Europe. World Health Organization 2018.

List of Medicines for Brand Consideration

List of medicines prescribers should consider prescribing by brand name in addition to active ingredient name if the inclusion of brand name is necessary for the clinical treatment of their patients.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
adrenaline (epinephrine) pre-filled auto-inject syringes	Delivery device continuity required	EpiPen 300 microgram/0.3 mL injection, 0.3 mL pen device	Adrenaline Mylan 300 microgram/0.3 mL injection, 0.3 mL pen device	✓	✓	Patient familiarity with one brand is important for optimal emergency use
adrenaline (epinephrine) pre-filled auto-inject syringes	Delivery device continuity required	EpiPen Jr 150 microgram/0.3 mL injection, 0.3 mL pen device	Adrenaline Jr Mylan 150 microgram/0.3 mL injection, 0.3 mL pen device	✓	✓	Patient familiarity with one brand is important for optimal emergency use
amphotericin B 50 mg powder for injection	Different formulations of the same active ingredient have different dosing and/or rates of administration	AmBisome amphotericin B (**liposomal amphotericin**) 50 mg powder for injection	N/A	✗	N/A	These different formulations have the same chemical name, but different dosing and/or rates of administration
amphotericin B 50 mg powder for injection	Different formulations of the same active ingredient have different dosing and/or rates of administration	Amphotericin B MYLAN (amphotericin B) 50 mg powder for injection vial	N/A	✗	N/A	These different formulations have the same chemical name, but different dosing and/or rates of administration

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
beclometasone diproprionate 50 microgram/ actuation	Different formulations of the same active ingredient have different dosing and/or rates of administration	▪ Qvar 50 microgram/ actuation inhalation pressurised inhalation ▪ Qvar 50 Autohaler	N/A	✓	N/A	–
beclometasone diproprionate 50 microgram/ actuation	Different formulations of the same active ingredient have different dosing and/or rates of administration	Beconase Allergy and Hayfever 50 microgram/ actuation aqueous nasal spray	N/A	✗	N/A	Beconase Allergy & Hayfever {beclometasone dipropionate 0.5 mg/g (50 microgram per actuation)} nasal spray is available as a PHARMACY MEDICINE (Schedule 2)
bifidobacterium bifidum, bifidobacterium infantis and lactobacillus acidophilus	Different formulations of the same active ingredient have different dosing and/or rates of administration	Labinic Drops	N/A	✗	✗	▪ For pre-term infants ▪ Helps enhance/promote healthy digestive system function in formula fed healthy infants ▪ Enhance/promote healthy digestion in formula fed healthy infants. Medicine unapproved by TGA, accessible through Special Access Scheme.
bifidobacterium infantis and lactobacillus acidophilus	Different formulations of the same active ingredient have different dosing and/or rates of administration	INFLORAN	N/A	✗	✗	▪ For pre-term infants ▪ Helps enhance/promote healthy digestive system function in formula fed healthy infants ▪ Enhance/promote healthy digestion in formula fed healthy infants

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
bimatoprost 0.03% eye drops, 3 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Lumigan	▪ Bimtop ▪ APO-Bimatoprost ▪ Bimatoprost Sanoz	✓	✓	Treatment for glaucoma – 'a' flagging across all brands
bimatoprost 0.03% eye drops, 30 × 0.4 mL unit doses	Similarity of active ingredient names will likely cause confusion and selection errors	Lumigan PF	N/A	✓	N/A	Treatment for glaucoma
bimatoprost 0.03% + timolol 0.5% eye drops, 3 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Ganfort 0.3/5	N/A	✓	N/A	Treatment for glaucoma
bimatoprost 0.03% + timolol 0.5% eye drops, 30 × 0.4 mL unit doses	Similarity of active ingredient names will likely cause confusion and selection errors	GANfort PF 0.3/5	N/A	✓	N/A	Treatment for glaucoma

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
botulinum toxin type A	Different brands of the same active ingredient have different dosing regimens for the same indications	Botox	N/A	✓	✗	**SPECIAL WARNINGS AND PRECAUTIONS FOR USE: Lack of interchangeability between botulinum toxin products** – DUE TO THE LACK OF AN INTERNATIONAL UNIT, BOTOX® IS NOT THERAPEUTICALLY EQUIVALENT TO ANY OTHER BOTULINUM TOXIN TYPE A PREPARATIONS. THE POTENCIES OF BOTOX® AND OTHER BOTULINUM TOXIN TYPE A PREPARATIONS ARE BASED ON DIFFERENT ASSAY METHODS. IN VIEW OF THIS LACK OF HARMONISATION OF UNIT SYSTEMS FOR BOTULINUM TOXIN TYPE A, EXTREME CAUTION IS REQUIRED IF IT SHOULD PROVE NECESSARY TO SUBSTITUTE THE BOTULINUM TYPE A TOXIN OF ONE PHARMACEUTICAL COMPANY BY ANOTHER. THE EFFECT OF ADMINISTERING DIFFERENT BOTULINUM NEUROTOXIN SEROTYPES AT THE SAME TIME OR WITHIN SEVERAL MONTHS OF EACH OTHER IS UNKNOWN. EXCESSIVE NEUROMUSCULAR WEAKNESS MAY BE EXACERBATED BY ADMINISTRATION OF ANOTHER BOTULINUM TOXIN PRIOR TO THE RESOLUTION OF THE EFFECTS OF A PREVIOUSLY ADMINISTERED BOTULINUM TOXIN. Different brands have different dose regimens for the same indications. Different administration (subcutaneous or intradermal), different dose regimens for the different indications.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
clostridium **botulinum type a toxin** – haemagglutinin complex	Different brands of the same active ingredient have different dosing regimens for the same indications	Dysport	N/A	✓	✗	Different brands have different dose regimens for the same indications. **Caution: ONE IPSEN UNIT is not equivalent to ONE UNIT of any other botulinum toxin preparation.**
inco**botulinum toxin A**	Different brands of the same active ingredient have different dosing regimens for the same indications	Xeomin	N/A	✓	✗	Different brands have different dose regimens for the same indications. **Caution: Unit doses recommended for Xeomin are not interchangeable with those for other preparations of botulinum toxin.**
brinzolamide 1% eye drops, 5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Azopt	BrinzoQuin	✓	✓	Treatment for glaucoma – 'a' flagging across all brands. Brand premium applies to originator brand
brinzolamide 1% + brimonidine tartrate 0.2% eye drops, 5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Simbrinza 1%/0.2%	N/A	✓	N/A	Treatment for glaucoma
brinzolamide 1% + timolol 0.5% eye drops, 5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Azarga	N/A	✓	N/A	Treatment for glaucoma
brimonidine tartrate 0.2% + timolol 0.5% eye drops, 5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Combigan	N/A	✓	N/A	Treatment for glaucoma

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
brimonidine tartrate 0.15% eye drops, 5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Alphagan P 1.5	N/A	✓	N/A	Treatment for glaucoma
brimonidine tartrate 0.2% eye drops, 5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Alphagan	Enidin	✓	✓	Treatment for glaucoma – 'a' flagging across all brands. Brand premium applies to originator brand
buprenorphine sublingual tablet/ tablet	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – **High-risk medicine (opioid)**	▪ **Subutex** sublingual tablet in 400 microgram, 2 mg and 8 mg strengths	▪ Temgesic 200 microgram sublingual tablet ▪ **Bupradex** tablet in 400 microgram, 2 mg and 8 mg strengths	✓	✗	Subutex sublingual tablet for opiate dependence is PBS listed
buprenorphine modified release injection	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – **High-risk medicine (opioid)**	▪ **Buvidal Weekly** modified-release injection, available in 8 mg, 24 mg or 32 mg strengths ▪ **Buvidal Monthly** modified release injection, available in 64 mg, 96 mg, 128 mg strengths	N/A	✓	✗	▪ Buvidal modified release injection comes in different strengths ▪ Available on PBS in 8 mg, 24 mg or 32 mg strengths for weekly injection ▪ Available on PBS in 64 mg, 96 mg, 128 mg strengths for monthly injection ▪ PBS listed for opiate dependence

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
buprenorphine modified release injection	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – **High-risk medicine (opioid)**	**Sublocade** modified release solution for injection, available in 100 mg/0.5 mL and 300 mg/1.5 mL strengths	N/A	✗	✗	Sublocade comes in 100 mg/0.5 mL and 300 mg/1.5 mL strengths indicated for opiate dependence, neither of which is PBS listed. **Caution: High dose modified release Sublocade 300 mg/1.5 mL injection should be prescribed by brand.**
buprenorphine + naloxone sublingual film; available in 2 mg/500 microgram and 8 mg/2 mg strengths	Different brands of the same active ingredient have different dosing regimens for specific licensed indicationss – **High-risk medicine (opioid)**	▪ **Suboxone** Film 2/0.5 sublingual film ▪ **Suboxone** Film 8/2 sublingual film	–	✓	N/A	For opiate dependence
buprenorphine + naloxone sublingual tablet; available in 2 mg/500 microgram and 8 mg/2 mg strengths	Different brands of the same active ingredient have different dosing regimens for the same indications – **High-risk medicine (opioid)**	▪ **Bupradone** 2/0.5 sublingual tablet ▪ **Bupradone** 8/2 sublingual tablet	N/A	✗	✗	For opiate dependence

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
buprenorphine + naloxone sublingual tablet; available in 2 mg/500 microgram and 8 mg/2 mg strengths	Different brands of the same active ingredient have different dosing regimens for the same indications – **High-risk medicine (opioid)**	**ZUBSOLV** sublingual tablet (available in 0.7 mg/0.18 mg, 1.4 mg/0.36 mg, 2.9 mg/0.71 mg, 5.7 mg/1.4 mg, 8.6 mg/2.1 mg, 11.4 mg/2.6 mg strengths)	MPL-Buprenorphine/ Naloxone sublingual tablet (available in 0.7 mg/0.18 mg, 1.4 mg/0.36 mg, 2.9 mg/0.71 mg, 5.7 mg/1.4 mg, 8.6 mg/2.1 mg, 11.4 mg/2.6 mg strengths)	✗	✗	For opiate dependence
buprenorphine (transdermal) patch, available in 5 microgram/hour, 10 microgram/hour, 15 microgram/hour, 20 microgram/hour, 25 microgram/hour, 30 microgram/hour, 40 microgram/hour	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – **High-risk medicine (opioid)**	Norspan 5 microgram/ hour patch, 2	▪ Buprenorphine Sandoz ▪ Bupredermal ▪ Bupretec ▪ Bupannus	✓	✓	▪ PBS listings for chronic severe disabling pain unresponsive to non-opioid analgesics, and/or for chronic severe disabling pain in patients receiving palliative care ▪ At strengths from 5 microgram/hour to 15 microgram/hour the PBS listed brands Norspan, Bupredermal, and Buprenorphine Sandoz are 'a' flagged ▪ Only Norspan is available on PBS in strengths from 20 microgram/hour and higher ▪ Bupretec and Bupannus brands are not PBS listed. Both are listed on ARTG in strengths from 5 microgram/hour through 40 microgram/hour

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
carbamazepine 200 mg tablet	Narrow therapeutic index (anti-epileptic)	Tegretol 200	▪ Carbamazepine Sandoz ▪ Teril	✓	✓	▪ When prescribing carbamazepine 200 mg specify by brand to eliminate confusion between immediate release tablet and modified release tablet ▪ Teril is not PBS listed
carbamazepine 200 mg modified release tablet	Narrow therapeutic index (anti-epileptic)	Tegretol CR 200	N/A	✓	✗	When prescribing carbamazepine 200 mg specify by brand to eliminate confusion between immediate release tablet and modified release tablet
ciclosPORIN 10 mg capsule, 60	Narrow therapeutic index (for certain indications)	Neoral 10 mg capsule	N/A	✓	N/A	–
ciclosPORIN 25 mg capsule, ciclosPORIN 50 mg capsule, ciclosPORIN 100 mg capsule	Narrow therapeutic index (for certain indications)	▪ Neoral 25 mg capsule ▪ Neoral 50 mg capsule ▪ Neoral 100 mg capsule	Cyclosporin Sandoz	✓	✓	CiclosPORIN must be prescribed and dispensed by brand name. Patients should be stabilised on a particular brand of oral ciclosPORIN because switching between formulations without close monitoring may lead to clinically important changes in blood-ciclosPORIN concentration. Switching between brand and generic formulations or between generic formulations should only be initiated by a transplant specialist.
ciclosPORIN 100 mg/mL oral liquid, 50 mL	Narrow therapeutic index (for certain indications)	Neoral	N/A	✓	N/A	–

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
ciclosPORIN 50 mg/mL injection, 10 × 1 mL ampoules	Narrow therapeutic index (for certain indications)	Sandimmun	N/A	✓	N/A	–
clozapine 50 mg tablet, clozapine 200 mg tablet	Narrow therapeutic index/**Highly Specialised Drug** (Section 100 HSD)	▪ Clopine 50 mg tablet ▪ Clopine 200 mg tablet	N/A	✓	N/A	Used to treat schizophrenia. There is one brand of clozapine at 50 mg and 200 mg strengths available in Australia – Clopine® from Hospira (now Pfizer). The specific brand patient monitoring system is Clopine Central™ for Clopine®.
clozapine 25 mg tablet, clozapine 100 mg tablet	Narrow therapeutic index/**Highly Specialised Drug** (Section 100 HSD)	▪ Clozaril 25 mg tablet ▪ Clozaril 100 mg tablet	▪ Clopine 25 mg tablet ▪ Clopine 100 mg tablet	✓	N/A	There are two brands of clozapine in the 25 mg and 100 mg tablet strengths available in Australia – Clozaril® from Novartis (now MYLAN) and Clopine® from Hospira (now Pfizer). Each of these brands of clozapine has an associated clozapine patient monitoring service – the Clozaril Patient Monitoring System (CPMS) for Clozaril® and Clopine Central™ for Clopine®.
clozapine 50 mg/mL oral liquid	Narrow therapeutic index/**Highly Specialised Drug** (Section 100 HSD)	Versacloz 50 mg/mL oral liquid, 100 mL	Clopine Suspension 50 mg/mL	✓	N/A	The brands VERSACLOZ and CLOPINE are not 'a' flagged on the PBS. **Caution: VERSACLOZ is not listed on the ARTG**.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
denosumab 60 mg/mL injection	Different brands of the same active ingredient have different dosing regimens for specific licensed indications -osteoporosis	Prolia 60 mg/mL injection, 1 mL syringe	N/A	✓	N/A	Denosumab 60 mg/mL injection used to treat osteoporosis with specific clinical criteria
denosumab 120 mg/1.7 mL injection	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – adjunct for cancer treatment	Xgeva 120 mg/1.7 mL injection, 1.7 mL vial	N/A	✓	N/A	Denosumab 120 mg/1.7 mL injection used to treat bone metastases from breast cancer or prostate cancer, and used to treat giant cell tumour of bone
dorzolamide 2% eye drops, 5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Trusopt	▪ Trusamide ▪ APO-Dorzolamide	✓	✓	Treatment for glaucoma – 'a' flagging across all brands
dorzolamide 2% + timolol 0.5% eye drops, 5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Cosopt	▪ Cosdor ▪ APO-Dorzolamide/ Timolol 20/5 ▪ Dorzolamide/ Timolol JUNO 20/5	✓	✓	▪ Treatment for glaucoma – 'a' flagging across all brands. Brand premium applies to originator brand ▪ Dorzolamide/Timolol JUNO 20/5 is not PBS listed

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
estradiol transdermal patches – 25 microgram/ 24 hours patch, 50 microgram/ 24 hours patch, 75 microgram/ 24 hours patch, 100 microgram/ 24 hours patch	Different brands of the same active ingredient have different dosing regimens for the same indications	Climara (used once a week)	N/A	✓	N/A	**Caution: specify by brand to avoid confusion with different dosing frequency**
estradiol transdermal patches – 25 microgram/ 24 hours patch, 37.5 microgram/ 24 hours patch, 50 microgram/ 24 hours patch, 75 microgram/ 24 hours patch, 100 microgram/ 24 hours patch	Different brands of the same active ingredient have different dosing regimens for the same indications	Estraderm MX (used twice a week)	Estradot (used twice a week)	✓	✓	No 'a' flagging across brands. **Caution: specify by brand to avoid confusion with different dosing frequency.**

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
fentanyl lozenge – 200 microgram, 400 microgram, 600 microgram, 800 microgram, 1200 microgram, 1600 microgram	Narrow therapeutic index – **High-risk medicine (opioid analgesic)**	Actiq lozenge	N/A	✓	N/A	–
fentanyl orally disintegrating tablet – 100 microgram, 200 microgram, 400 microgram, 600 microgram, 800 microgram	Narrow therapeutic index – **High-risk medicine (opioid analgesic)**	Fentora orally disintegrating tablet	N/A	✓	N/A	–
fentanyl sublingual tablet – 100 microgram, 200 microgram, 300 microgram, 400 microgram, 600 microgram, 800 microgram	Narrow therapeutic index – **High-risk medicine (opioid analgesic)**	Abstral sublingual tablet	N/A	✓	N/A	–
fentanyl (as fentanyl citrate) 100 microgram or 400 microgram per actuation nasal spray solution with metered dose pump	Narrow therapeutic index – **High-risk medicine (opioid analgesic)**	PECFENT Fentanyl (as fentanyl citrate) 100 microgram or 400 microgram per actuation nasal spray solution with metered dose pump	N/A	✗	N/A	–

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
fentanyl patches	Narrow therapeutic index – **High-risk medicine (opioid)**	Durogesic patches, 12 microgram/hour, 25 microgram/hour, 50 microgram/hour, 100 microgram/hour	▪ Denpax ▪ Dutran ▪ Fenpatch ▪ Fentanyl Sandoz ▪ APO-Fentanyl	✓	✓	Fentanyl patches are available as matrix* and reservoir formulations. Reservoir patches must not be cut because damage to the rate-limiting membrane can lead to rapid release of fentanyl resulting in overdose. Risk of abuse with reservoir patches. **Caution: DUROGESIC, FENPATCH, DENPAX, DUTRAN, FENATNYL SANDOZ and APO-FENTANYL BRANDS OF PATCHES SHOULD NOT BE CUT NOR DIVIDED. DAMAGED PATCHES SHOULD NOT BE USED AS IT USES DRUG-IN-ADHESIVE RESERVOIR TECHNOLOGY.**
flupentixol decanoate 20 mg/mL injection	Different formulation release characteristics – **High-risk medicine (antipsychotic)**	Fluanxol Depot 20 mg/mL injection, 5 × 1 mL ampoules	N/A	✓	N/A	Fluanxol (flupenthixol decanoate) is not intended for short-term therapy (less than 3 months) and is administered by intramuscular injection, in the gluteus maximus. **Fluanxol is NOT for intravenous use. Caution: specify by brand to avoid confusion between different strength depot injections.**

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
flupentixol decanoate 100 mg/mL injection	Different formulation release characteristics – **High-risk medicine (antipsychotic)**	Fluanxol Concentrated Depot 100 mg/mL injection, 5 × 1 mL ampoules	N/A	✓	N/A	**Caution: Doses greater than 100 mg/ fortnight are usually not deemed necessary although higher doses have been used occasionally in some treatment-resistant patients. Patients who require higher doses of Fluanxol Depot to control symptoms of schizophrenia and/or those who complain of discomfort with a large injection volume may be administered Fluanxol Concentrated Depot (100 mg/mL) in preference to Fluanxol Depot (20 mg/mL).**
fluticasone propionate	Similarity of active ingredient names will likely cause confusion and mix-ups	FLIXOTIDE ACCUHALER	N/A	✓	N/A	Inhalation devices – may not be interchangeable
fluticasone furoate	Similarity of active ingredient names will likely cause confusion and mix-ups	ARNUITY ELLIPTA	N/A	✓	N/A	Inhalation devices – may not be interchangeable
fluticasone furoate + valanterol trifenatate	Similarity of active ingredient names will likely cause confusion and mix-ups	BREO ELLIPTA	N/A	✓	N/A	Inhalation devices – may not be interchangeable
fluticasone furoate + umeclidinium bromide + vilanterol trifenatate	Similarity of active ingredient names will likely cause confusion and mix-ups	TRELEGY ELLIPTA	N/A	✓	N/A	Inhalation devices – may not be interchangeable

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
follitropin alfa 300 units (22 microgram)/ 0.5 mL injection, 5 × 0.5 mL pen devices	Different formulations of the same biosimilar active ingredient have different dosing and/or rates of administration.	BEMFOLA	N/A	✓	N/A	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different and not interchangeable. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.
follitropin alfa 300 units (21.84 microgram)/ 0.5 mL injection, 0.5 mL pen device	Different formulations of the same biosimilar active ingredient have different dosing and/or rates of administration.	GONAL-F Pen	N/A	✓	N/A	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different and not interchangeable. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.
follitropin alfa 450 units (33 microgram)/ 0.75 mL injection, 5 × 0.75 mL pen devices	Different formulations of the same biosimilar active ingredient have different dosing and/or rates of administration	BEMFOLA	N/A	✓	N/A	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different and not interchangeable. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
follitropin alfa 450 units (32.76 microgram)/ 0.75 mL injection, 0.75 mL pen device	Different formulations of the same biosimilar active ingredient have different dosing and/or rates of administration	GONAL-F Pen	N/A	✓	N/A	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different and not interchangeable. User training is required. Use of the biosimilar name alone could lead to prescribing, dispensing and administration errors. This item is not 'a' flagged.
formoterol fumarate dihydrate 12 microgram/ actuation powder for inhalation	Delivery device continuity required	OXIS Turbuhaler 12 microgram/actuation powder for inhalation, 60 actuations used with TURBUHALER inhalation device	Foradile 12 microgram powder for inhalation, 60 capsules used with AEROLIZER inhalation device	✓	✓	Dry powder devices – may not be interchangeable
HYDROmorphone hydrochloride 4 mg tablet, HYDROmorphone hydrochloride 8 mg tablet	Different formulation release characteristics – **High-risk medicine (opioid analgesic)**	▪ Dilaudid 4 mg tablet, 20 ▪ Dilaudid 8 mg tablet, 20	N/A	✓	N/A	**Caution: Specify brand for immediate release formulation of high-risk medicine (opioid analgesic)**
HYDROmorphone hydrochloride 4 mg modified release tablet, HYDROmorphone hydrochloride 8 mg modified release tablet	Different formulation release characteristics – **High-risk medicine (opioid analgesic)**	▪ Jurnista 4 mg modified release tablet, 14 ▪ Jurnista 8 mg modified release tablet, 14	N/A	✓	N/A	**Caution: Specify brand for modified release formulation of high-risk medicine (opioid analgesic)**

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
HYDROmorphone hydrochloride 10 mg/mL injection, 5 × 1 mL ampoules	Similarity of active ingredient names will likely cause confusion and mix-ups – **High-risk medicine (opioid anlagesic)**	Dilaudid-HP 10 mg/mL injection	▪ HYDROMORPHONE JUNO-HP ▪ MEDSURGE HYDROMORPHONE HP 10mg/1 mL	✓	✓	**Caution: Specify by brand to avoid confusion with other morphine salts and HYDROmorphone in 10 mg/mL injections**
morphine hydrochloride trihydrate 10 mg/mL injection, 5 × 1 mL ampoules	Similarity of active ingredient names will likely cause confusion and mix-ups – **High-risk medicine (opioid anlagesic)**	Morphine Juno 10 mg/mL	N/A	✓	N/A	**Caution: specify by brand to avoid confusion with other morphine salts and HYDROmorphone in 10 mg/mL injections**
morphine sulfate pentahydrate 10 mg/mL injection, 5 × 1 mL ampoules	Similarity of active ingredient names will likely cause confusion and mix-ups – **High-risk medicine (opioid anlagesic)**	Morphine Sulfate 10 mg/1 mL MEDSURGE	Morphine Sulfate 10 mg/1 mL Hospira	✓	✓	**Caution: specify by brand to avoid confusion with other morphine salts and HYDROmorphone in 10 mg/mL injections**
insulin	Narrow therapeutic index – **High-risk medicine (insulin)**	There are many insulin products that include the same, or very similar, active ingredient names which could lead to prescribing, dispensing and administration errors	–	–	–	Patient familiarity with one brand is important, as instructions for use vary between preparations. Pen devices are different. User training is required. Where there are many preparations that include the same, or very similar, generic name which could lead to prescribing, dispensing and administration errors.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
insulin glargine	Narrow therapeutic index – **High-risk medicine (insulin) – regular dose**	Optisulin Solostar 100 units/mL	Semglee 100 units/ml	✓	✓	Optisulin brand and Semglee brand are available in 100 units/mL injection. Toujeo brand are available in 300 units/mL injection. The dispensing pens are different. The different brands have different dose regimens. The generic/biosimilar brand of insulin glargine 100 units/mL injection is 'a' flagged with Optisulin brand.
insulin glargine	Narrow therapeutic index – **High-risk medicine (insulin) – high dose**	Toujeo Solostar 300 units/mL	N/A	✓	N/A	Toujeo brand is available in 300 units/mL injection, Optisulin Solostar brand and the SEMGLEE brand are available in 100 units/ mL injection. The dispensing pens are different. Different brands have different dose regimens. **Caution: specify by brand to avoid supply of incorrect strength of insulin glargine.**
insulin aspart	Narrow therapeutic index – **High-risk medicine (insulin) – fast acting**	Fiasp FlexTouch 100 units/mL fast acting injection	N/A	✓	N/A	Fiasp is an ultra-fast acting insulin for subcutaneous administration. Fiasp administered 0–2 minutes before the start of a meal produced a significantly greater postmeal glucose lowering effect after a standardised meal test compared to NovoRapid. Administration of Fiasp up to 20 minutes after starting a meal was as efficacious as NovoRapid given before a meal.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
insulin aspart	Narrow therapeutic index – **High-risk medicine (insulin)**	NovoRapid FlexPen and Penfill	N/A	✓	N/A	NovoRapid has a faster onset and a shorter duration of action than soluble human insulin. Due to the faster onset of action, insulin aspart products should generally be given immediately before a meal or when necessary, soon after the start of a meal.
interferon beta-1a 6 million units (30 microgram)/ 0.5 mL injection	Similarity of active ingredient names will likely cause confusion and selection errors	**Avonex** 6 million units (30 microgram)/0.5 mL injection, 4 × 0.5 mL syringes	N/A	✓	N/A	No 'a' flagging across brands
interferon beta-1a 12 million units (44 microgram)/ 0.5 mL injection	Similarity of active ingredient names will likely cause confusion and selection errors	**Rebif 44** interferon beta-1a 12 million units (44 microgram)/0.5 mL injection, 12 × 0.5 mL **pen devices** **Rebif 44** interferon beta-1a 12 million units (44 microgram)/0.5 mL injection, 12 × 0.5 mL **syringes**	N/A	✓	N/A	No 'a' flagging across brands
iron polymaltose 100 mg/2 mL injection	Different brands of the same active ingredient have different dosing regimens for the same indications	Ferrosig 100 mg/2 mL injection, 5 × 2 mL ampoules	N/A	✓	N/A	Dose administered by intramuscular injection or intravenous infusion

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
iron sucrose 100 mg/5 mL injection	Different brands of the same active ingredient have different dosing regimens for the same indications	Venofer 100 mg/5 mL injection, 5 × 5 mL ampoules	N/A	✓	N/A	Dose administered by intravenous infusion
itraconazole	Different brands of the same active ingredient have different dosing regimens for the same indications	Lozanoc	N/A	✓	N/A	Can be given with or without food. This preparation is not interchangeable with other itraconzole preparations
itraconazole	Different brands of the same active ingredient have different dosing regimens for the same indications	Sporanox	▪ Itracap ▪ Itranox ▪ APO-Itraconazole	✓	✓	Must be taken with food. This preparation is not interchangeable with other itraconazole preparations.
itraconazole	Different brands of the same active ingredient have different dosing regimens for the same indications	Sporanox	N/A	✗	N/A	Must be taken on ampty stomach 1 hour beifore food or 2 hours after food. This preparation is not interchangeable with other itraconazole preparations.
latanoprost 0.005% eye drops, 2.5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Xalatan	▪ Xalaprost ▪ Apotex ▪ Actavis ▪ Sandoz generics	✓	✓	Treatment for glaucoma – ‘a’ flagging across all brands

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
latanoprost 0.005% + timolol 0.5% eye drops, 2.5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Xalacom	▪ Xalamol 50/5 ▪ Apotex ▪ Sandoz generics	✓	✓	Treatment for glaucoma – 'a' flagging across all brands
leuprorelin acetate 7.5 mg modified release injection [1 chamber] (&) inert substance diluent [1 mL chamber], 1 dual chamber syringe	Different brands of the same active ingredient have different dosing regimens for specific approved indications	**Lucrin Depot 7.5 mg PDS** modified release injection [1 chamber] (&) inert substance diluent [1 mL chamber], 1 dual chamber syringe	N/A	✓	N/A	Specific brand for a specific indication – LUCRIN brand is for precocious puberty
leuprorelin acetate 7.5 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack – 7.5 mg	Different brands of the same active ingredient have different dosing regimens for specific licensed indications	**Eligard 1 month 7.5 mg** modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack	N/A	✓	N/A	Specific brand for a specific indication – ELIGARD brand is for prostate cancer
leuprorelin acetate 22.5 mg modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe	Different brands of the same active ingredient have different dosing regimens for specific approved indications	**Lucrin Depot 3 Month PDS 22.5 mg** modified release injection [1 chamber] (&) inert substance diluent [1.5 mL syringe], 1 dual chamber syringe	N/A	✓	N/A	Specific brand for a specific indication – LUCRIN brand in this strength is locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
leuprorelin acetate 30 mg modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe	Different brands of the same active ingredient have different dosing regimens for specific approved indications	**Lucrin Depot 4 Month PDS 30 mg** modified release injection [1 chamber] (&) inert substance diluent [1.5 mL syringe], 1 dual chamber syringe	N/A	✓	N/A	Specific brand for a specific indication – LUCRIN brand in this strength is locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
leuprorelin acetate 30 mg modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe	Different brands of the same active ingredient have different dosing regimens for specific approved indications	**Lucrin Depot Paediatric 30 mg PDS** modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe	N/A	✓	N/A	Specific brand for a specific indication – LUCRIN brand is for precocious puberty
leuprorelin acetate 30 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe]	Different brands of the same active ingredient have different dosing regimens for specific licensed indications	**Eligard 4 month 30 mg** modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack	N/A	✓	N/A	Specific brand for a specific indication – ELIGARD brand is for prostate cancer

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
leuprorelin acetate 45 mg modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe	Different brands of the same active ingredient have different dosing regimens for specific approved indications	**Lucrin Depot 6 Month 45 mg** modified release injection [1 chamber] (&) inert substance diluent [1.5 mL chamber], 1 dual chamber syringe	N/A	✓	N/A	Specific brand for a specific indication – LUCRIN brand in this strength is locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
leuprorelin acetate 45 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe]	Different brands of the same active ingredient have different dosing regimens for specific licensed indications	**Eligard 6 month 45 mg** modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack	N/A	✓	N/A	Specific brand for a specific indication – ELIGARD brand is for prostate cancer
levodopa + benserazide immediate release, available in 50 mg/12.5 mg, 100 mg/25 mg, 200 mg/50 mg strengths in capsule and 100 mg/25 mg strength in tablet	Different formulations of the same active ingredient have different release characteristsics	**Madopar** 62.5 capsule, 100	N/A	✓	N/A	–

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
levodopa + benserazide dispersible tablet, available in 50 mg/12.5 mg, and 100 mg/25 mg strength	Different formulations of the same active ingredient have different release characteristsics.	**Madopar Rapid** 62.5 dispersible tablet, 100	N/A	✓	N/A	–
levodopa + benserazide modified release capsule, available in 100 mg/25 mg strength	Different formulations of the same active ingredient have different release characteristsics.	**Madopar HBS** modified release capsule, 100	N/A	✓	N/A	–
levothyroxine sodium – 50 microgram, 75 microgram, 100 microgram, 200 microgram tablet	Narrow therapeutic index	Oroxine tablet, 200, 50 microgram, 75 microgram, 100 microgram, 200 microgram tablet	Eutroxsig tablet, 200 50 microgram, 75 microgram, 100 microgram, 200 microgram tablet	✓	✓	Both brands are 'a' flagged at all PBS listed strengths

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
levothyroxine sodium	Narrow therapeutic index	Eltroxin	N/A	N/A	N/A	**Caution: ELTROXIN is not bioequivalent on a same-dose basis with EUTROXSIG/ OROXINE**. If a decision is made to switch a patient from EUTROXSIG/OROXINE to ELTROXIN, then prescribers should have a plan for monitoring TSH. Prescribers should be aware that dose adjustment may be required. Prescribers should tell their patients not to interchange ELTROXIN and EUTROXSIG/OROXINE unless a decision has been made to switch products, and there is a plan for monitoring TSH levels and review of dose.
lithium carbonate 250 mg tablet	Narrow therapeutic index	Lithicarb 250 mg tablet, 200	N/A	✓	N/A	**Caution: Specify by brand to avoid supply of incorrect strength**
lithium carbonate 450 mg modified release tablet	Narrow therapeutic index	Quilonum SR 450 mg modified release tablet, 100	N/A	✓	N/A	**Caution: Specify by brand to avoid supply of incorrect strength**
methylphenidate hydrochloride modified release capsule – 10 mg, 20 mg, 30 mg, and 40 mg strengths	Different formulations of the same active ingredient have different release characteristsics. Schedule 8 medicine.	Ritalin LA 10 mg modified release capsule, 30	N/A	✓	N/A	Ritalin LA capsules contain half the dose as immediate release beads and half the dose as enteric coated, delayed-release beads. The proportion of immediate release and modified release drug is unique to the Ritalin LA brand.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
methylphenidate hydrochloride modified release tablet – 18 mg, 27 mg, 36 mg and 54 mg strengths	Different formulations of the same active ingredient have different release characteristsics. Schedule 8 medicine.	Concerta 18 mg modified release tablet, 30	N/A	✓	N/A	Concerta tablets are extended release, with a drug overcoat, and two internal drug layers. The proportion of immediate release and modified release drug is unique to the Concerta brand.
methylprednisolone sodium succinate 40 mg injection	Different formulations of the same active ingredient have different dosing and/or rates of administration	Solu-medrol 40 mg injection [1 vial] (&) inert substance diluent [1 mL vial], 1 pack	Methylpred 40 mg injection, 5 vials	✓	✓	▪ Intramuscular use for less than or equal to 250 mg dose only ▪ Intravenous use for all doses (administration times change). **Caution: Specify brand to avoid confusion with methylprednisolone acetate formulations**.
methylprednisolone acetate 40 mg/mL injection	Different formulations of the same active ingredient have different dosing and/or rates of administration	Depo-medrol 40 mg/mL injection, 5 × 1 mL vials	Depo-Nisolone 40 mg/mL injection, 5 × 1 mL vials	✓	✓	Methylprednisolone acetate should not be administered by any route other than intramuscular, intra-articular, soft tissue or intralesional injection, and then for treatment of specific conditions or diseases. **Caution: Specify brand to avoid confusion with methylprednisolone sodium succinate formulations**.
methylprednisolone aceptonate 0.1% ointment	Different formulations of the same active ingredient have different dosing and/or rates of administration	Advantan	N/A	✓	N/A	The active ingredient of both Advanta Ointment and Advantan Fatty Ointment is the same – the ointment is suitable for dry, fissured, scaly or hyperkeratinised skin areas

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
methylprednisolone aceptonate 0.1% ointment	Different formulations of the same active ingredient have different dosing and/or rates of administration	Advantan (Fatty)	N/A	✓	N/A	The active ingredient of both Advantan Ointment and Advantan Fatty Ointment is the same – the Fatty ointment has an occlusive effect and is indicated for psoriasis treatment areas where the stratum corneum is particularly thick, i.e. elbows, knees, palms, and soles.
morphine sulfate pentahydrate 10 mg tablet	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (opioid analgesic)**	Sevredol 10 mg tablet	N/A	✓	N/A	Morphine sulfate pentahydrate 10 mg tablets are an immediate release formulation. **Caution: Specify by brand to avoid confusion with modified release 10 mg tablets**.
morphine sulfate pentahydrate 10 mg modified release capsule	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (opioid analgesic)**	Kapanol 10 mg modified release capsule	N/A	✓	N/A	Kapanol (Morphine sulfate pentahydrate) capsules contain identical polymer-coated sustained-release pellets of the active ingredient. The PI for MS Contin states 'It is not possible to ensure bioequivalence between different brands of modified release morphine products. Therefore, caution is needed when changing between different brands of sustained or modified release morphine, or other strong opioid analgesic preparations, and the patient should be re-titrated and clinically re-assessed.' **Caution: Specify by brand to avoid confusion with immediate release 10 mg tablets**.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
morphine sulfate pentahydrate 10 mg modified release tablet	Different formulations of the same active ingredient have different release characteristics – **High-risk medicine (opioid analgesic)**	MS Contin 10 mg modified release tablet	▪ Morphine MR Apotex ▪ Momex SR 10 ▪ Morphine MR AN ▪ Morphine MR Mylan	✓	✓	Morphine sulfate pentahydrate 10 mg modified release tablets are 'a' flagged on PBS with the generic brands and can be safely prescribed by active ingredient. **Caution: Specify by brand to avoid confusion with immediate release 10 mg tablets**.
morphine sulfate pentahydrate 30 mg tablet	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (opioid analgesic)**	Anamorph 30 mg tablet	N/A	✓	N/A	Morphine sulfate pentahydrate 30 mg tablets are an immediate release formulation. **Caution: Specify by brand to avoid confusion with modified release 30 mg tablets**.
morphine sulfate pentahydrate 30 mg modified release capsule	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (opioid analgesic)**	MS Mono 30 mg modified release capsule	N/A	✓	N/A	**Caution: Specify by brand to avoid confusion with immediate release 30 mg tablets**
morphine sulfate pentahydrate 30 mg modified release tablet	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (opioid analgesic)**	MS Contin 30 mg modified release tablet	▪ Morphine MR Apotex ▪ Momex SR 10 ▪ Morphine MR AN ▪ Morphine MR Mylan	✓	✓	Morphine sulfate pentahydrate 30 mg modified release tablets are 'a' flagged on PBS with the generic brands and can be safely prescribed by active ingredient. **Caution: Specify by brand to avoid confusion with immediate release 10mg tablets**.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
mycophenolate mofetil 250 mg capsule	Narrow therapeutic index (immunosuppressant) – Similarity of active ingredient names will likely cause confusion and selection errors	CellCept 250 mg capsule, 100	▪ Mycophenolate NLS ▪ MYTIL/Mycokem/ ALCEPT/Pharmacor Mycophenolate/ MOFIT ▪ MyAccord ▪ Mycocept ▪ TRANCEPT/ CellPlant ▪ Aspen-Mycophenolate/ CelMuno/Imulate ▪ APO-Mycophenolate ▪ Ceptolate ▪ Mycophenolate AN ▪ Mycophenolate SANDOZ	✓	✓	Switching between brand and generic formulations or between generic formulations should only be initiated by a transplant specialist

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
mycophenolate mofetil 500 mg tablet	Narrow therapeutic index (immunosuppressant) – Similarity of active ingredient names will likely cause confusion and selection errors	CellCept 500 mg tablet, 50	▪ APO-Mycophenolate ▪ Ceptolate ▪ MycoCept ▪ Mycophenolate AN ▪ Mycophenolate APOTEX ▪ Mycophenolate GH ▪ Mycophenolate SANDOZ ▪ Pharmacor Mycophenolate 500	✓	✓	Switching between brand and generic formulations or between generic formulations should only be initiated by a transplant specialist
mycophenolate enteric tablet – 180 mg and 360 mg strengths	Narrow therapeutic index (immunosuppressant) – Similarity of active ingredient names will likely cause confusion and selection errors	Myfortic 180 mg enteric tablet, 120	N/A	✓	N/A	For prophylaxis of renal allograft rejection – careful monitoring of patients is mandatory. Management includes initiation, stabilisation and review of therapy as required.
Oral contraceptive pills	Similarity of active ingredient names will likely cause confusion and sellection errors	There are many oral contraceptive products that include the same, or very similar, active ingredient names which could lead to prescribing, dispensing and administration errors	–	–	–	–

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
oxycodone hydrochloride immediate release tablet, available in 5 mg strength	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (opioid analgesic)**	Endone 5 mg tablet, 20	▪ Oxycodone Aspen ▪ Mayne Pharma Oxycodone IR	✓	✓	Oxycodone hydrochloride 5 mg tablet is an immediate release formulation. **Caution: Specify by brand to avoid confusion with modified release doseforms**.
oxycodone hydrochloride immediate release capsule, available in 5 mg, 10 mg and 20 mg strengths	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (opioid analgesic)**	OxyNorm 10 mg capsule, 20	Oxycodone BNM	✓	✓	Oxycodone hydrochloride 10 mg capsule is an immediate release formulation. **Caution: Specify by brand to avoid confusion with modified release 10 mg capsule**.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
oxycodone hydrochloride modified release tablet, avaialble in 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, and 80 mg strengths	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (opioid analgesic)**	OxyContin 10 mg modified release tablet, 28	Novacodone/ Oxycodone Sandoz	✓	✓	Oxycodone hydrochloride 10 mg tablet is a modified release formulation. **Caution: Specify by brand to avoid confusion with modified release 10 mg capsule**. Both OxyContin and Novacodone tablets are modified release tablets designed to provide delivery of oxycodone over 12 hours – and comprise a matrix formulation with a hydrogelling property. Oxycodone hydrochloride modified release tablets in 10 mg, 20 mg, 40 mg and 80 mg strengths are 'a' flagged on PBS with generic brands and can be safely prescribed by active ingredient. The 15 mg and 30 mg strengths of oxycodone hydrochloride modified release tablets are only available under the OxyContin brand.
paliperidone palmitate modified release injection, 1 syringe – 25 mg, 50 mg, 75 mg, 100 mg, 150 mg	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (antipsychotic)**	Invega Sustenna 25 mg modified release injection, 1 syringe	N/A	✓	N/A	Paliperidone modified release injection in 25 mg, 50 mg, 75 mg, 100 mg and 150 mg strengths for **1 month treatment** of schizophrenia. **Caution: Specify by brand to avoid confusion with Invega Trinza modified release injections**.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
paliperidone palmitate modified release injection, syringe – 175 mg/0.875 mL, 263 mg/1.315 mL, 350 mg/1.75 mL, 525 mg/2.625 mL	Different formulations of the same active ingredient have different release characteristsics – **High-risk medicine (antipsychotic)**	Invega Trinza 175 mg/0.875 mL modified release injection, 0.875 mL syringe	N/A	✓	N/A	Paliperidone modified release injection in 175 mg, 263 mg, 350 mg, and 525 mg strengths for 3 months treatment of schizophrenia. **Caution: Specify by brand to avoid confusion with Invega Sustenna modified release injections**.
primidone 250 mg tablet	Narrow therapeutic index (anti-epileptic)	APO-Primidone 250 mg tablet, 100	N/A	✓	N/A	There is no 'a' or 'b' flagging across both brands of primidone.
primidone 250 mg tablet	Narrow therapeutic index (anti-epileptic)	Mysoline 250 mg tablet, 200	N/A	✓	N/A	There is no 'a' or 'b' flagging across both brands of primidone.
TACrolimus capsule, 500 microgram, 1 mg, and 5 mg strengths	Narrow therapeutic index	Prograf 1 mg capsule, 100	▪ Pacrolim ▪ Pharmacor Tacrolimus ▪ Tacrolimus Apotex ▪ Tacrograf ▪ Tacrolimus Sandoz	✓	✓	Switching between brand and generic formulations or between generic formulations should only be initiated by a transplant specialist. All immediate release capsule formulations of TACrolimus at 500 microgram, 1 mg, and 5 mg strengths are 'a' flagged on PBS.
TACrolimus modified release capsule, 60–500 microgram, 1 mg, 3 mg and 5 mg strengths	Narrow therapeutic index	Advagraf XL 1 mg modified release capsule, 60	N/A	✓	N/A	–
theophylline 133.3 mg/25 mL oral liquid	Narrow therapeutic index	Nuelin 133.3 mg/25 mL oral liquid, 500 mL	N/A	✓	N/A	–

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
theophylline modified release tablet, available in 100–200 mg, 250 mg, and 300 mg strengths	Narrow therapeutic index	Nuelin-SR 200 mg modified release tablet, 100	N/A	✓	N/A	–
timolol 0.5% eye drops, 2.5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Timoptol XE	N/A	✓	N/A	Treatment for glaucoma
timolol 0.5% eye drops, 5 mL	Similarity of active ingredient names will likely cause confusion and selection errors	Timoptol	N/A	✓	N/A	Treatment for glaucoma
tRAMadol 50 mg (oral) modified release	Narrow therapeutic index – **High-risk medicine (opioid)**	Tramal SR 50 mg modified release tablet, 20	N/A	✓	N/A	tRAMadol hydrochloride modified release tablets are 'a' flagged on PBS with the generic brands and can be safely prescribed by active ingredient for the 100 mg, 150 mg, and 200 mg strengths. However the 50mg modified release tablet is only available under the Tramal SR 50 brand. **Caution is required when prescribing tRAMadol 50 mg strength as both modified release tablets (Tramal SR) and immediate release capsules (Tramal) are available under the Tramal brand.**

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
tRAMadol 50 mg (oral) immediate release	Narrow therapeutic index – **High-risk medicine (opioid)**	Tramal 50mg capsule	▪ Zydol ▪ APO-Tramadol/ Chem mart Tramadol/Terry White Chemists Tramadol ▪ Tramadol AMNEAL/ Tramadol AN ▪ Tramadol SCP ▪ Tramadol Sandoz ▪ Tramedo	✓	✓	tRAMadol hydrochloride immediate release capsules are 'a' flagged on PBS with the generic brands and can be safely prescribed by active ingredient. **Caution is required when prescribing tRAMadol 50 mg strength as both modified release tablets (Tramal SR) and immediate release capsules (Tramal) are available under the Tramal brand.**
trastuzumab 60 mg injection	Similarity of active ingredient names will likely cause confusion and selection errors	Herceptin 60 mg injection	N/A	✓	N/A	Treatment for metastatic (Stage IV) HER2 positive breast cancer. **Caution: Potential for confusion between an antibody and antibody-medicine conjugate. Caution: 60 mg injection only available in originator/reference brand.**
trastuzumab 150 mg injection	Similarity of active ingredient names will likely cause confusion and selection errors	Herceptin 150 mg injection	▪ **Ogivri 150 mg** ▪ Herzuma 150 mg ▪ Kanjinti 150 mg ▪ Ontruzant 150 mg	✓	✓	Treatment for metastatic (Stage IV) HER2 positive breast cancer. **Caution: Potential for confusion between an antibody and antibody-medicine conjugate.**
trastuzumab 420 mg injection	Similarity of active ingredient names will likely cause confusion and selection errors	Kanjinti 420 mg injection	N/A	✓	✓	Treatment for metastatic (Stage IV) HER2 positive breast cancer. **Caution: Potential for confusion between an antibody and antibody-medicine conjugate. Caution: 420 mg injection only available in originator/reference brand.**

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
trastuzumab emtasine injection, available in 100 mg, and 160 mg strengths	Similarity of active ingredient names will likely cause confusion and selection errors	Kadcyla 100 mg injection, 1 vial	N/A	✓	N/A	Potential for confusion between an antibody and antibody-medicine conjugate
ulipristal acetate 5 mg tablet	Different brands of the same active ingredient have different dosing regimens for specific approved indications	Esmya 5 mg tablet	N/A	✗	✗	Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator that acts via high-affinity (nanomolar) binding to the human progesterone receptor. ESMYA ulipristal acetate 5 mg is **indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age**.
ulipristal acetate 30 mg tablet	Different brands of the same active ingredient have different dosing regimens for specific approved indications	EllaOne uliptristan acetate 30 mg tablet	N/A	✗	✗	Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator that acts via high-affinity (nanomolar) binding to the human progesterone receptor. EllaOne ulipristal acetate 30 mg is **indicated for emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure**.
warfarin 1 mg, 2 mg, and 5 mg tablet	Not therapeutically equivalent	Coumadin	N/A	✓	✓	There is no 'a' or 'b' flagging across both brands of warfarin
warfarin 1 mg, 3 mg, and 5 mg tablet	Not therapeutically equivalent	Marevan	N/A	✓	✓	There is no 'a' or 'b' flagging across both brands of warfarin

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
zoledronic acid 5 mg/100 mL injection	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – Bisphosphonate for treatment of osteoporosis and Paget's Disease	Aclasta 5 mg/100 mL injection, 100 mL vial	▪ Osteovan ▪ Zoledronate-RZ ▪ Zolaccord ▪ Zoledronic Acid SUN ▪ Zoledasta ▪ GenRx Zoledronic Acid ▪ Zoledasta ▪ Skelezol	✓	✓	Aclasta is used to treat osteoporosis. The different strengths 5 mg/5 mL injection 100 mL vial ('a' flagged brands on PBS are Aclasta, Osteovan, Zoledasta) and 5 mg/100 mL injection 100 mL bag ('a' flagged brand on PBS is Ostira – no generic available) do raise concerns and potential confusion between brands may be unsafe or lead to a clinically significant difference in clinical response.
zoledronic acid 5 mg/100 mL injection	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – Bisphosphonate for treatment of osteoporosis	Ostira 5 mg/100 mL injection, 100 mL bag	N/A	✓	N/A	Ostira is used to treat osteoporosis. While no generic is available in 100 mL bag, it is 'a' flagged on PBS with the different brands of 5 mg/5 mL injection, 100 mL vial ('a' flagged brands on PBS are Aclasta, Osteovan, Zoledasta). To avoid confusion between injection doseforms, for safety and/or avoiding a clinically significant difference in response consider prescribing by brand.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
zoledronic acid 4 mg/100 mL injection	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – Bisphosphonate for treatment of hypercalcaemia of malignancy	DBL Zoledronic Acid 4 mg/100 mL injection, 100 mL bag	N/A	✓	N/A	DBL Zolendronic Acid is used to treat multiple myeloma, bone metasteses, and hypercalcaemia of malignancy. While no generic is available in 100 mL bag, it is 'a' flagged on PBS with the different brands of 4 mg/5 mL injection, 100 mL vial ('a' flagged brands on PBS are Zometa, Deztron, APO-Zoledronic aacid). To avoid confusion between injection doseforms, for safety and/or avoiding a clinically significant difference in response consider prescribing by brand.
zoledronic acid 4 mg/5 mL injection	Different brands of the same active ingredient have different dosing regimens for specific licensed indications – Bisphosphonate for treatment of hypercalcaemia of malignancy	Zometa 4 mg/5 mL injection, 5 mL vial	▪ APO-Zoledonic acid ▪ DBL Zoledronic Acid ▪ DEZTRON ▪ Claris Lifesciences Zoledronic Acid	✓	✓	Zometa is used to lower the amount of calcium in the blood when it becomes too high, as may happen in some forms of cancer. Zometa is also used to slow down the spread of cancers in bone, helping to prevent changes to the bones that may cause them to weaken. The different strengths 4 mg/5 mL injection 5 mL vial and 4 mg/100 mL injection 100 mL bag do raise concerns and potential confusion between brands may be unsafe or lead to a clinically significant difference in clinical response.

INN (active ingredient name)	Principle	Originator/ reference brand	Generic/ biosimilar brand	Originator/ reference brand PBS listed	Generic/ biosimilar brand PBS listed	Notes
zuclopenthixol decanoate	Different formulations of the same active ingredient have different release characteristsics. – **High-risk medicine (antipsychotic)**	Clopixol Depot 200 mg/mL injection, 5 × 1 mL ampoules	N/A	✓	N/A	Maintenance treatment of acute psychoses, mania and exacerbation of chronic psychoses. May be an advantage in the treatment of noncompliant patients.
zuclopenthixol acetate	Different formulations of the same active ingredient have different release characteristsics. – **High-risk medicine (antipsychotic)**	▪ Clopixol Acuphase 50 mg/mL, 5 × 1 mL ampoules ▪ Clopixol Acuphase 100 mg/2 mL, 5 × 2 mL ampoules	N/A	✗	N/A	Initial treatment of acute psychoses, mania and exacerbation of chronic psychoses

AUSTRALIAN COMMISSION
ON SAFETY AND QUALITY IN HEALTH CARE

Level 5, 255 Elizabeth Street, Sydney NSW 2000
GPO Box 5480, Sydney NSW 2001

Phone: (02) 9126 3600

@ACSQHC

safetyandquality.gov.au